Sugi Predict

Sugi Predict / Compounds / SCHEMBL14700732

SCHEMBL14700732

SCHEMBL14700732

Cc1ccc(-c2ccc(Cl)cc2)cc1C1=C(O)[C@]2(CC[C@](O)(C(F)(F)F)CC2)NC1=O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 13/20 0.77
▸ ACACA Q13085 13/20 0.77
▸ JAK2 O60674 1/20 0.34
▸ NTRK1 P04629 1/20 0.34
▸ MET P08581 1/20 0.34
▸ FGFR1 P11362 1/20 0.34
▸ PRKACA P17612 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ MAP2K2 P36507 1/20 0.34
▸ FLT3 P36888 1/20 0.34
▸ GSK3B P49841 1/20 0.34
▸ MAP2K1 Q02750 1/20 0.34
▸ MST1R Q04912 1/20 0.34
▸ NTRK3 Q16288 1/20 0.34
▸ NTRK2 Q16620 1/20 0.34
▸ CAMK1D Q8IU85 1/20 0.34
▸ PDK2 Q15119 1/20 0.34
▸ TDP2 O95551 1/20 0.34
▸ MGAT2 Q10469 1/20 0.34
▸ ORAI1 Q96D31 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2351011 1.00 ACACB (0.77) ACACBACACAJAK2NTRK1MET
SCHEMBL14689370 1.00 ACACB (0.77) ACACBACACAJAK2NTRK1MET
SCHEMBL2353461 0.90 ACACB (0.83) ACACBACACAJAK2NTRK1MET
SCHEMBL14700734 0.90 ACACB (0.65) ACACBACACANTRK1FLT3GSK3B
SCHEMBL2348346 0.90 ACACB (0.65) ACACBACACANTRK1FLT3GSK3B
SCHEMBL14689257 0.90 ACACB (0.65) ACACBACACANTRK1FLT3GSK3B
SCHEMBL14700733 0.89 ACACB (0.78) ACACBACACANTRK1FLT3GSK3B
SCHEMBL14676053 0.89 ACACB (0.78) ACACBACACANTRK1FLT3GSK3B
SCHEMBL2355252 0.89 ACACB (0.78) ACACBACACANTRK1FLT3GSK3B
SCHEMBL12479148 0.87 ACACB (0.76) ACACBACACAJAK2NTRK1MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9278925-B2 Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-03-08 — — US disclosed
US-9278925-B2 Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-03-08 — — US disclosed
US-20140275199-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-18 — — US disclosed
US-20140275199-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-18 — — US disclosed
US-20130040935-A1 CYCLIC KETO-ENOLS FOR THERAPY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-14 — — US disclosed
US-20130040935-A1 CYCLIC KETO-ENOLS FOR THERAPY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275199-A1 SUBSTITUTED 3-(BIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE MALT1, UGT1A3, BMI1 ACACB 1121/4885ACACA 1826/4885JAK2 1435/4885
US-20130040935-A1 CYCLIC KETO-ENOLS FOR THERAPY AKR1B1, AKR1C3, AKR1A1 ACACB 310/4885ACACA 541/4885JAK2 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback